biocryst is terminating bcx5191 program, page-3

Biocryst terminated the program on no efficacy on a low dose, even though the dose was well tolerated - talk about being on the ropes - they are really scraping the barrel now.

Seems to me that there is still plenty of scope for Biota to take their HCV compound further before any thought of scaling back the resources...remember that Plumb/Patti know the HCV game well.